Name | Title | Contact Details |
---|---|---|
Beth Kaufman |
Executive Vice President, Chief Legal Officer and Corporate Secretary | Profile |
Joe Bonaccorsi |
Executive VIce President and General Counsel | Profile |
Andrea Kochensparger |
Vice President, Deputy General Counsel | Profile |
Rekha Hanu |
Vice President, Associate General Counsel and Chief IP Counsel | Profile |
Medicine Hat Office is a Medicine Hat, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
In Harmony Inc is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
The Hydropothecary is a licensed producer and distributor of medical marijuana under Health Canada`s Access to Cannabis for Medical Purposes Regulations (ACMPR). We are committed to medical excellence and achieve this through our growing techniques, process control, quality assurance testing, robust research and development, and by offering an exceptional customer service experience. We are proud of our company`s remarkable growth thus far and look forward to our continued expansion with the construction of a new greenhouse which will boast an additional 250,000 sq/ft in 2018. We are constantly seeking skilled, energetic and highly focused p-professionals who would like the opportunity to be a part of our team and of an exciting industry that is constantly evolving.
AccuMed Inc. is a Lawrence Township, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).